NICE evidence summary (new medicines) on aclidinium bromide for chronic obstructive pulmonary disease

Source: NICE Area: Evidence > Drug Specific Reviews 'Evidence summaries: new medicines' are provided to help commissioners, budget holders and groups such as Area Prescribing Committees to make informed decisions and aid local planning on the introduction of key new medicines. They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, that are considered to be of significance to the NHS. The topics selected are medicines that have recently gone into the UK market, or medicines that may be marketed in the UK in the next 6-12 months. The strengths and weaknesses of the relevant evidence are critically reviewed.   The subject of this summary (ESNM8) is the use of aclidinium bromide (Eklira Genuair), an inhaled long-acting muscarinic antagonist (LAMA), for maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).  Key points from the evidence highlighted are as ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news